1
|
Shi Y, Luo J, Wang X, Zhang Y, Zhu H, Su D, Yu W, Tian J. Emerging Trends on the Correlation Between Neurotransmitters and Tumor Progression in the Last 20 Years: A Bibliometric Analysis via CiteSpace. Front Oncol 2022; 12:800499. [PMID: 35280754 PMCID: PMC8907850 DOI: 10.3389/fonc.2022.800499] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 01/31/2022] [Indexed: 01/15/2023] Open
Abstract
Background Bibliometric analysis is used to gain a systematic understanding of developments in the correlation between neurotransmitters and tumor progression in research hotspots over the past 20 years. Methods Relevant publications from the Web of Science Core Collection (WoSCC) were downloaded on August 1, 2021. Acquired data were then analyzed using the Online Analysis Platform of Literature Metrology (http://biblimetric.com) and the CiteSpace software to analyze and predict trends and hot spots in this field. Results A total of 1310 publications on neurotransmitters and tumor progression were identified, and 1285 qualified records were included in the final analysis. The country leading the research was the United States of America. The University of Buenos Aires featured the highest number of publications among all institutions. Co-citation cluster labels revealed the characteristics of 10 main clusters: beta-adrenergic receptors (β-AR), glutamate, neurotransmitters, serotonin, drd2, histamine, glycine, interleukin-2, neurokinin receptor-1, and nicotinic acetylcholine receptors (AchRs). Keywords and references burst detection indicated that apart from β-AR, dopamine receptor and cancer types like gastric cancer and glioblastoma are the newly emerging research hotspots. Conclusions This study analyzed 1285 publications and 39677 references covering the topic of neurotransmitters and tumor progression and showed that while β-AR has always been a hot topic in this field, dopamine receptor is an emerging target for this research field, and gastric cancer and glioblastoma are the top two tumors that have garnered increasing attention and have become the focal point of recent studies.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Weifeng Yu
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Jie Tian
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| |
Collapse
|
2
|
The Function of the Histamine H4 Receptor in Inflammatory and Inflammation-Associated Diseases of the Gut. Int J Mol Sci 2021; 22:ijms22116116. [PMID: 34204101 PMCID: PMC8200986 DOI: 10.3390/ijms22116116] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 05/31/2021] [Accepted: 06/03/2021] [Indexed: 02/07/2023] Open
Abstract
Histamine is a pleiotropic mediator involved in a broad spectrum of (patho)-physiological processes, one of which is the regulation of inflammation. Compounds acting on three out of the four known histamine receptors are approved for clinical use. These approved compounds comprise histamine H1-receptor (H1R) antagonists, which are used to control allergic inflammation, antagonists at H2R, which therapeutically decrease gastric acid release, and an antagonist at H3R, which is indicated to treat narcolepsy. Ligands at H4R are still being tested pre-clinically and in clinical trials of inflammatory diseases, including rheumatoid arthritis, asthma, dermatitis, and psoriasis. These trials, however, documented only moderate beneficial effects of H4R ligands so far. Nevertheless, pre-clinically, H4R still is subject of ongoing research, analyzing various inflammatory, allergic, and autoimmune diseases. During inflammatory reactions in gut tissues, histamine concentrations rise in affected areas, indicating its possible biological effect. Indeed, in histamine-deficient mice experimentally induced inflammation of the gut is reduced in comparison to that in histamine-competent mice. However, antagonists at H1R, H2R, and H3R do not provide an effect on inflammation, supporting the idea that H4R is responsible for the histamine effects. In the present review, we discuss the involvement of histamine and H4R in inflammatory and inflammation-associated diseases of the gut.
Collapse
|
3
|
UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells. J Immunother 2020; 42:162-174. [PMID: 30933043 DOI: 10.1097/cji.0000000000000261] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Herein we demonstrate that ultraviolet light-inactivated Herpes Simplex Virus-1 (UV-HSV-1) stimulates peripheral blood mononuclear cells (PBMCs) to lyse both androgen-sensitive and androgen-independent prostate cancer (PrCA) cell lines, but not the benign prostatic hyperplastic epithelial cell line, BPH-1, and is 1000-10,000-fold more potent at stimulating this killing than ultraviolet light-inactivated Vesicular Stomatitis Virus, adenovirus, reovirus or cytomegalovirus. Among PBMCs, natural killer (NK) cells appear to be a major cell type involved in this killing and UV-HSV-1 appears to directly and potently stimulate NK cell expression of CD69, degranulation, cytokine production, and migration to IL-8 in PC3 conditioned medium. We also found that UV-HSV-1 stimulates glycolysis in PBMCs and NK cells, and that 2-deoxyglucose and the protein kinase C inhibitor, Go6976, and the NFκB inhibitor, Bay 11-7082, all abrogate UV-HSV-1 activated killing of PC3 cells by PBMCs and NK cells. Using neutralizing anti-Toll-like receptor 2 (TLR2) we found that UV-HSV-1, like HSV-1, activates NK cells via TLR2. Taken together, these results are consistent with Toll-like receptor 2 ligands on UV-HSV-1 stimulating TLR2 on NK cells to activate protein kinase C, leading to enhanced glycolysis and NFκB activation, both of which play a critical role in this anti-PrCA innate immune response. Importantly, UV-HSV-1 synergizes with IL-15 to increase the cytolytic activity of PBMCs against PC3 cells and there was considerable donor-to-donor variation in killing ability. These results support the preclinical development of UV-HSV-1 as an adjuvant, in combination with IL-15, for cell infusions of healthy, preselected NK cells to treat PrCA.
Collapse
|
4
|
Monti Hughes A, Longhino J, Boggio E, Medina VA, Martinel Lamas DJ, Garabalino MA, Heber EM, Pozzi ECC, Itoiz ME, Aromando RF, Nigg DW, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new "B2" configuration of the RA-6 nuclear reactor. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2017; 56:377-387. [PMID: 28871389 DOI: 10.1007/s00411-017-0710-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 08/22/2017] [Indexed: 06/07/2023]
Abstract
Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We demonstrated, in 2001, the therapeutic effect of BNCT mediated by BPA (boronophenylalanine) in the hamster cheek pouch model of oral cancer, at the RA-6 nuclear reactor. Between 2007 and 2011, the RA-6 was upgraded, leading to an improvement in the performance of the BNCT beam (B2 configuration). Our aim was to evaluate BPA-BNCT radiotoxicity and tumor control in the hamster cheek pouch model of oral cancer at the new "B2" configuration. We also evaluated, for the first time in the oral cancer model, the radioprotective effect of histamine against mucositis in precancerous tissue as the dose-limiting tissue. Cancerized pouches were exposed to: BPA-BNCT; BPA-BNCT + histamine; BO: Beam only; BO + histamine; CONTROL: cancerized, no-treatment. BNCT induced severe mucositis, with an incidence that was slightly higher than in "B1" experiments (86 vs 67%, respectively). BO induced low/moderate mucositis. Histamine slightly reduced the incidence of severe mucositis induced by BPA-BNCT (75 vs 86%) and prevented mucositis altogether in BO animals. Tumor overall response was significantly higher in BNCT (94-96%) than in control (16%) and BO groups (9-38%), and did not differ significantly from the "B1" results (91%). Histamine did not compromise BNCT therapeutic efficacy. BNCT radiotoxicity and therapeutic effect at the B1 and B2 configurations of RA-6 were consistent. Histamine slightly reduced mucositis in precancerous tissue even in this overly aggressive oral cancer model, without compromising tumor control.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina.
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina.
| | - Juan Longhino
- Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, San Carlos de Bariloche, Province Rio Negro, Argentina
| | - Esteban Boggio
- Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, San Carlos de Bariloche, Province Rio Negro, Argentina
| | - Vanina A Medina
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
- Laboratory of Tumoral Biology and Inflammation, School of Medical Sciences, Institute for Biomedical Research (BIOMED CONICET-UCA), Pontifical Catholic University of Argentina (UCA), Ciudad Autonoma de Buenos Aires, Argentina
| | - Diego J Martinel Lamas
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
- Laboratory of Tumoral Biology and Inflammation, School of Medical Sciences, Institute for Biomedical Research (BIOMED CONICET-UCA), Pontifical Catholic University of Argentina (UCA), Ciudad Autonoma de Buenos Aires, Argentina
| | - Marcela A Garabalino
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
| | - Elisa M Heber
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
| | - María E Itoiz
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
- Department of Oral Pathology, Faculty of Dentistry, UBA, Ciudad Autonoma de Buenos Aires, Argentina
| | - Romina F Aromando
- Department of Oral Pathology, Faculty of Dentistry, UBA, Ciudad Autonoma de Buenos Aires, Argentina
| | | | - Verónica A Trivillin
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
| | - Amanda E Schwint
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
| |
Collapse
|
5
|
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission. Curr Treat Options Oncol 2015; 15:171-86. [PMID: 24792016 DOI: 10.1007/s11864-014-0281-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Although it is absolutely clear that postremission therapy is currently necessary to obtain disease-free long-term survivorship for patients with acute myeloid leukemia (AML) in first complete remission (CR), it is not entirely clear what form that treatment should take. High-dose cytarabine is clearly effective and there definitely is a dose-response relationship for cytarabine and remission duration. High-dose cytarabine is effective for younger patients but not elderly patients. It is effective for patients with favorable cytogenetics but it is not clear whether it is effective for patients with intermediate or unfavorable cytogenetics. Furthermore, it is not clear what the most effective and least toxic dose and schedule of high-dose cytarabine is.
Collapse
|